Details for Patent: 10,993,942

Which drugs does patent 10,993,942 protect, and when does it expire?

Patent 10,993,942 protects VENCLEXTA and is included in one NDA.

This patent has twenty-one patent family members in ten countries.

Summary for Patent: 10,993,942

Title:	Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
Abstract:	The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
Inventor(s):	Sampath; Deepak (South San Francisco, CA), Klein; Christian (Iffeldorf, DE), Fairbrother; Wayne John (South San Francisco, CA), Enschede; Sari L. Heitner (River Forest, IL), Humerickhouse; Rod A. (Highland Park, IL), Roberts; Andrew W. (Melbourne, AU), Seymour; John F. (Melbourne, AU)
Assignee:	GENENTECH, INC. (South San Francisco, CA) HOFFMANN-LA ROCHE INC. (Little Falls, NJ) ABBVIE INC. (North Chicago, IL)
Application Number:	16/827,650
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 10,993,942

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-001	Apr 11, 2016		RX	Yes	No						TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) BY ORALLY ADMINISTERING VENETOCLAX TO AN ADULT ACCORDING TO A DOSE RAMP-UP THAT INCLUDES A DOSE OF 50 MG PER DAY FOR 1 WEEK FOLLOWED BY 100 MG PER DAY FOR 1 WEEK
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-002	Apr 11, 2016		RX	Yes	No						TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) BY ORALLY ADMINISTERING VENETOCLAX TO AN ADULT ACCORDING TO A DOSE RAMP-UP THAT INCLUDES A DOSE OF 50 MG PER DAY FOR 1 WEEK FOLLOWED BY 100 MG PER DAY FOR 1 WEEK
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-003	Apr 11, 2016		RX	Yes	Yes						TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) BY ORALLY ADMINISTERING VENETOCLAX TO AN ADULT ACCORDING TO A DOSE RAMP-UP THAT INCLUDES A DOSE OF 50 MG PER DAY FOR 1 WEEK FOLLOWED BY 100 MG PER DAY FOR 1 WEEK

International Family Members for US Patent 10,993,942

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2884307
China	104768581
China	111437386
China	111481552
European Patent Office	2892557